Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method and apparatus for optical inhibition of photodynamic therapy

a photodynamic therapy and optical inhibition technology, applied in the field of optical inhibition of photodynamic therapy, can solve the problems of non-selective accumulation of precursor photosensitizers and/or photosensitizers, unintended damage to non-targeted healthy surface tissue during subsequent pdt treatment, etc., and achieve the effect of preventing or reducing the extent or likelihood of unwanted damag

Inactive Publication Date: 2015-08-27
THE GENERAL HOSPITAL CORP
View PDF6 Cites 12 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention provides methods and devices for preventing or reducing damage to epithelial tissue during photodynamic therapy (PDT) treatment. The invention involves applying an inhibiting radiation to an anatomical structure to prevent the formation of photosensitizers in epithelial tissue and then activating the photosensitizers at the targeted treatment site using a treatment radiation. The invention can also include cooling the surface of the tissue being treated to reduce discomfort and inhibit metabolism of pre-photosynthesizers. The technical effects of the invention include reducing the likelihood of unwanted damage to non-targeted tissue and promoting more effective treatment.

Problems solved by technology

Although various photosensitizer and ALA-induced PDT techniques provide an effective treatment for many conditions, accumulation of precursor photosensitizers and / or photosensitizers may generally not be selective.
Thus, the precursor photosensitizer can metabolize into a photosensitizer in both surface tissue and underlying targeted tissue, thereby potentially causing unintended damage to non-targeted, healthy surface tissue during subsequent PDT treatment.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method and apparatus for optical inhibition of photodynamic therapy
  • Method and apparatus for optical inhibition of photodynamic therapy
  • Method and apparatus for optical inhibition of photodynamic therapy

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0120]Suppression of epidermal porphyrin accumulation by blue light exposure during ALA metabolism, in accordance with exemplary embodiments of the present invention, was tested in humans. With reference to FIG. 6, a 20% topical ALA solution was applied to human skin 610, covered with aluminum foil 620, while only some uncovered areas received 410-nm blue light (1.47 mW / cm2) 630 during the incubation time. A fluorescent photo 640 was taken after 2 hours of incubation, and 632-nm light (100 J / cm2) was then applied to all areas 650. A clinical photograph 660 was taken after PDT treatment.

[0121]Blue light exposure during the period of ALA metabolism was observed to suppressed porphyrin accumulation and subsequent PDT reactions. Inactivation of porphyrin synthetic enzymes or the pre-porphyrin metabolites, concurrent repair of oxidative damage during blue light exposure, and / or changes in cell signaling may contribute to this observed effect. Such findings indicate that exemplary embodim...

example 2

[0123]In accordance with embodiments of the present invention, 20% topical ALA was applied to the skin of a pig. Nine different areas were divided and different attenuating films were placed over the skin during the entire incubation time (or the metabolism period). The attenuating films reduced the light transmittance allowing a range of irradiance varying from 100%, 56%, 44%, 35%, 26%, 21%, 19% to 17% of light during the incubation period.

[0124]Immediately after the drug application, a 410 nm blue light was irradiated through all the experiment sites at an irradiance of 2.6 mW / cm2 for 3 hours. During this period, porphyrin accumulation was measured in each test area by digital fluorescence photography (˜410 nm excitation, >600 nm emission), and microscopically determined by fluorescence microscopy of skin biopsies (8 mm diameter) obtained prior to light exposure. After the 3 hours of incubation, red light at 635 nm exposure with 200 J / cm2 fluence was delivered at 100 mW / cm2 irradi...

example 3

[0126]Embodiments of the present invention were used to treat a 23 year old female Asian patient exhibiting moderate to severe inflammatory acne (acne III-IV). The patient's recalcitrant acne was resistant to conventional treatments (oral and topical antibiotics, topic retinoids and benzoyl peroxide), and failed to respond to Accutane treatment (2 cycles). A 20% ALA solution (Dusa Pharmaceutics) was applied topically to the patient's face. The right side of the patient's face was covered with saran wrap and aluminum foil for 3 hours of incubation (to provide a conventional PDT treatment), while blue light at very low intensity (an inhibiting radiation) was applied to the left side of the patient's face for 3 hours (using a Clearlight at 90 W / cm2, provided about 2 meters from the patient).

[0127]After the incubation period, both sides of the face were irradiated with red light treatment radiation (635 nm wavelength, at about 180 J / cm2, using an Aktilite). During the red light irradiat...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A system and method are provided for preventing damage to the epidermis or other epithelial or non-target tissue during photodynamic therapy treatment. For example, an inhibiting radiation can be used to control formation of a photosensitizer from a precursor photosensitizer in the epidermis or epithelial tissue. Subsequent application of a treatment radiation can activate the photosensitizer to damage or destroy target sites while the non-target tissue remains substantially unaffected.

Description

CROSS REFERENCE TO RELATED APPLICATIONS[0001]The present application is a continuation of U.S. patent application Ser. No. 12 / 647,032, filed on Dec. 24, 2009, and entitled “METHOD AND APPARATUS FOR OPTICAL INHIBITION OF PHOTODYNAMIC THERAPY,” which itself is a continuation-in-part of PCT International Application No. PCT / US08 / 068593, filed on Jun. 27, 2008, entitled “METHOD AND APPARATUS FOR OPTICAL INHIBITION OF PHOTODYNAMIC THERAPY,” which itself claims priority from U.S. Provisional Application Ser. No. 60 / 946,536, filed on Jun. 27, 2007, entitled “METHOD AND APPARATUS FOR OPTICAL INHIBITION OF PHOTODYNAMIC THERAPY,” each of which is hereby incorporated by reference in its entirety.FIELD OF THE INVENTION[0002]The present invention relates to methods and apparatus for protecting non-target tissue (e.g., epithelial tissue) during photodynamic therapy using optical inhibition.BACKGROUND[0003]Photodynamic therapy (“PDT”) generally involves a local or systemic application of a light-a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61N5/06A61K41/00
CPCA61K41/0071A61N2005/0658A61K41/0061A61K41/0057A61N5/062A61N5/0616A61N2005/0662
Inventor SAKAMOTO, FERNANDA HIDEMIANDERSON, RICHARD ROXFARINELLI, WILLIAM A.DOUKAS, APOSTOLOS G.
Owner THE GENERAL HOSPITAL CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com